Page 22 - சிங்கப்பூர் பொருளாதார வளர்ச்சி பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioNTech SE: BioNTech Announces First Quarter 2021 Financial Results and Corporate Update

BioNTech SE: BioNTech Announces First Quarter 2021 Financial Results and Corporate Update More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021 Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond Announced planned expansion of global footprint to Asia with establishment of first regional headquarters for south east Asia in Singapore, including a fully-integrated and state-of-the art mRNA manufacturing facility In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials

United statesUnited kingdomSouth africaSanofi libtayoSylke maasUgur sahinFosun pharmaAutogene cevumeranUs centers for diseaseSingaporean economic development boardInternational olympic committeeBayer animal healthDevelopment expensesEuropean unionGlobal external communicationsAssociation for cancer immunotherapy

(BNTX), Pfizer, Inc (NYSE:PFE) - BioNTech Stock Jumps As It Plans New mRNA Manufacturing Facility In Singapore By 2023

(BNTX), Pfizer, Inc (NYSE:PFE) - BioNTech Stock Jumps As It Plans New mRNA Manufacturing Facility In Singapore By 2023
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Ugur sahinSingapore economic development boardSoutheast asiaசிங்கப்பூர் பொருளாதார வளர்ச்சி பலகைதென்கிழக்கு ஆசியா

BioNTech to establish its first regional hub for Asia Pacific in Singapore

BioNTech to establish its first regional hub for Asia Pacific in Singapore Details Expected to be operationally ready by 2023, the facility is expected to create 80 jobs for locals. Germany pharmaceutical company, BioNTech, maker of the Pfizer-BioNTech which currently protects from three Covid-19 variants, is setting up its first Asia Pacific office in Singapore creating employment opportunities for people in the Republic. The move, announced on 10 May, is part of the company’s bid to expand its global footprint in Asia through this SEA regional headquarters. In addition, the German company is also looking to establish an mRNA manufacturing facility here. The new facility, supported by the Singapore Economic Development Board (EDB), will provide regional and global supply capacity of its growing pipeline of mRNA-based product candidates, as well as a rapid response production capability to address potential pandemic threats in the region.

Sanofi pasteurAsia pacificUgur sahinSingapore economic development boardBeh swan ginசனோஃபி பாஸ்டர்ஆசியா பெஸிஃபிக்சிங்கப்பூர் பொருளாதார வளர்ச்சி பலகைபெஹ அன்னம் ஜின்

BioNTech announces new facility in Singapore

Article by Amanda Doyle BIONTECH has announced that it will build an mRNA manufacturing facility in Singapore as well as establish its regional headquarters for Southeast Asia there. BioNTech, in partnership with Pfizer, has developed an mRNA Covid-19 vaccine. It is also developing patient-specific cancer immunotherapies. It currently has more than 20 product candidates with ten candidates in ongoing clinical trials. The new manufacturing facility will be established with support from the Singapore Economic Development Board. The facility will have highly automated mRNA production capabilities for drug substance, drug product, and fill-and-finish. It will be able to produce a range of mRNA vaccines and therapeutics for infectious diseases and cancer, and will have a production capacity of several hundred million mRNA doses depending on the vaccine. It will provide regional and global supply capacity for BioNTech’s mRNA-based product candidates and will also enable a rapid respo

Ugur sahinSingapore economic development boardSoutheast asiaSingapore economic developmentSwan ginEconomic development boardசிங்கப்பூர் பொருளாதார வளர்ச்சி பலகைதென்கிழக்கு ஆசியாசிங்கப்பூர் பொருளாதார வளர்ச்சிஅன்னம் ஜின்பொருளாதார வளர்ச்சி பலகை

BioNTech to create mRNA manufacturing facility in Singapore

BioNTech plans to expand its global footprint with a regional headquarters for South East Asia in Singapore; as well as a fully integrated mRNA manufacturing facility. The new manufacturing base, established with support from the Singapore Economic Development Board, will provide regional and global supply capacity of mRNA-based product candidates, a well as offering rapid response production capability for the region for future pandemic threats. It will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The envisioned site will bring automated and end-to-end mRNA production capabilities across drug substance, drug product and fill-and-finish, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines.

United kingdomUgur sahinSingapore economic development boardSoutheast asiaஒன்றுபட்டது கிஂக்டம்சிங்கப்பூர் பொருளாதார வளர்ச்சி பலகைதென்கிழக்கு ஆசியா